252 related articles for article (PubMed ID: 22042697)
1. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.
D'Souza S; del Prete D; Jin S; Sun Q; Huston AJ; Kostov FE; Sammut B; Hong CS; Anderson JL; Patrene KD; Yu S; Velu CS; Xiao G; Grimes HL; Roodman GD; Galson DL
Blood; 2011 Dec; 118(26):6871-80. PubMed ID: 22042697
[TBL] [Abstract][Full Text] [Related]
2. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
[TBL] [Abstract][Full Text] [Related]
3. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
4. Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis.
Petrusca DN; Toscani D; Wang FM; Park C; Crean CD; Anderson JL; Marino S; Mohammad KS; Zhou D; Silbermann R; Sun Q; Kurihara N; Galson DL; Giuliani N; Roodman GD
J Hematol Oncol; 2018 Oct; 11(1):123. PubMed ID: 30286780
[TBL] [Abstract][Full Text] [Related]
5. Identification of the GATA factor TRPS1 as a repressor of the osteocalcin promoter.
Piscopo DM; Johansen EB; Derynck R
J Biol Chem; 2009 Nov; 284(46):31690-703. PubMed ID: 19759027
[TBL] [Abstract][Full Text] [Related]
6. XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the
Adamik J; Silbermann R; Marino S; Sun Q; Anderson JL; Zhou D; Xie XQ; Roodman GD; Galson DL
Front Endocrinol (Lausanne); 2018; 9():344. PubMed ID: 30008697
[TBL] [Abstract][Full Text] [Related]
7. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.
Mendoza-Villanueva D; Zeef L; Shore P
Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690
[TBL] [Abstract][Full Text] [Related]
8. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
Giuliani N; Colla S; Morandi F; Lazzaretti M; Sala R; Bonomini S; Grano M; Colucci S; Svaldi M; Rizzoli V
Blood; 2005 Oct; 106(7):2472-83. PubMed ID: 15933061
[TBL] [Abstract][Full Text] [Related]
9. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.
Xu G; Liu K; Anderson J; Patrene K; Lentzsch S; Roodman GD; Ouyang H
Blood; 2012 May; 119(18):4205-14. PubMed ID: 22427205
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
Fowler JA; Mundy GR; Lwin ST; Edwards CM
Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
[TBL] [Abstract][Full Text] [Related]
11. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
12. Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation.
Lu X; Beck GR; Gilbert LC; Camalier CE; Bateman NW; Hood BL; Conrads TP; Kern MJ; You S; Chen H; Nanes MS
J Bone Miner Res; 2011 Jan; 26(1):209-19. PubMed ID: 20683885
[TBL] [Abstract][Full Text] [Related]
13. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha.
Gilbert L; He X; Farmer P; Rubin J; Drissi H; van Wijnen AJ; Lian JB; Stein GS; Nanes MS
J Biol Chem; 2002 Jan; 277(4):2695-701. PubMed ID: 11723115
[TBL] [Abstract][Full Text] [Related]
14. Decrease of MiR-31 induced by TNF-α inhibitor activates SATB2/RUNX2 pathway and promotes osteogenic differentiation in ethanol-induced osteonecrosis.
Yu L; Xu Y; Qu H; Yu Y; Li W; Zhao Y; Qiu G
J Cell Physiol; 2019 Apr; 234(4):4314-4326. PubMed ID: 30132874
[TBL] [Abstract][Full Text] [Related]
15. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.
Takeuchi K; Abe M; Hiasa M; Oda A; Amou H; Kido S; Harada T; Tanaka O; Miki H; Nakamura S; Nakano A; Kagawa K; Yata K; Ozaki S; Matsumoto T
PLoS One; 2010 Mar; 5(3):e9870. PubMed ID: 20360846
[TBL] [Abstract][Full Text] [Related]
16. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
17. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2.
Sowa H; Kaji H; Hendy GN; Canaff L; Komori T; Sugimoto T; Chihara K
J Biol Chem; 2004 Sep; 279(39):40267-75. PubMed ID: 15150273
[TBL] [Abstract][Full Text] [Related]
18. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
Zdzisińska B; Bojarska-Junak A; Dmoszyńska A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2008; 56(3):207-21. PubMed ID: 18512025
[TBL] [Abstract][Full Text] [Related]
19. [Role of transcription factor special AT-rich binding protein 2 in the osteoblasts differentiation of bone marrow stromal cells].
Wang Q; Yu YC; Gu ZY; Bi W; Sun J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2011 Jun; 46(6):360-4. PubMed ID: 21914381
[TBL] [Abstract][Full Text] [Related]
20. MiR-214 inhibits human mesenchymal stem cells differentiating into osteoblasts through targeting β-catenin.
Li JP; Zhuang HT; Xin MY; Zhou YL
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4777-4783. PubMed ID: 29164587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
